Efficacy and Safety of Rivaroxaban Prophylaxis Compared With Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism
Phase of Trial: Phase III
Latest Information Update: 22 Nov 2017
At a glance
- Drugs Rivaroxaban (Primary)
- Indications Venous thromboembolism
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms CASSINI
- Sponsors Janssen Research & Development
- 15 Nov 2017 Planned End Date changed from 13 Jul 2018 to 30 Aug 2018.
- 12 Sep 2017 Rationale and desing published in the Thrombosis and Haemostasis.
- 23 Aug 2017 This trial has been completed in Germany.